BR0116662A - Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos - Google Patents

Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos

Info

Publication number
BR0116662A
BR0116662A BR0116662-0A BR0116662A BR0116662A BR 0116662 A BR0116662 A BR 0116662A BR 0116662 A BR0116662 A BR 0116662A BR 0116662 A BR0116662 A BR 0116662A
Authority
BR
Brazil
Prior art keywords
ring
alpha
receptor antagonists
adrenergic receptor
compounds
Prior art date
Application number
BR0116662-0A
Other languages
English (en)
Inventor
Cyrus Kephra Becker
Joan Marie Caroon
Chris Richard Melville
Fernando Padilla
Juerg Roland Pfister
Xiaoming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0116662A publication Critical patent/BR0116662A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"DERIVADOS DE QUINAZOLONA COMO ANTAGONISTAS RECEPTORES ALFA 1A/B ADRENéRGICOS". A invenção refere-se a compostos que são de uma forma geral antagonistas alfa-1A/B adrenoceptores e que são representados pela fórmula (I) em que Z é -C(O)- ou -S(O)~ 2~-, X é carbono ou nitrogênio, Y é carbono, e X-Y considerados juntos são dois átomos adjacentes do anel A, dito anel sendo um anel aromático fundido de cinco a seis átomos por anel opcionalmente incorporando um ou dois heteroátomos por anel, selecionados de N, O ou S; e os outros substituintes são como definidos no relatório descritivo; ou isómeros individuais, misturas racêmicas ou não racêmicas de isómeros, ou sais ou solvatos farmaceuticamente aceitáveis destes. A invenção ainda refere-se a composições farmacêuticas contendo tais compostos, métodos para a sua preparação e seu uso como agentes terapêuticos.
BR0116662-0A 2001-01-02 2001-12-17 Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos BR0116662A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25933701P 2001-01-02 2001-01-02
US32526701P 2001-09-27 2001-09-27
PCT/EP2001/014885 WO2002053558A1 (en) 2001-01-02 2001-12-17 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists

Publications (1)

Publication Number Publication Date
BR0116662A true BR0116662A (pt) 2003-09-23

Family

ID=26947245

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116662-0A BR0116662A (pt) 2001-01-02 2001-12-17 Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos

Country Status (16)

Country Link
EP (1) EP1363899B1 (pt)
JP (1) JP4031363B2 (pt)
KR (1) KR100554813B1 (pt)
CN (1) CN1237060C (pt)
AR (1) AR035775A1 (pt)
AT (1) ATE295362T1 (pt)
BR (1) BR0116662A (pt)
CA (1) CA2432578C (pt)
DE (1) DE60110844T2 (pt)
ES (1) ES2241891T3 (pt)
MX (1) MXPA03005854A (pt)
PA (1) PA8536001A1 (pt)
PE (1) PE20020735A1 (pt)
UY (1) UY27109A1 (pt)
WO (1) WO2002053558A1 (pt)
ZA (1) ZA200305038B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
BRPI0412285A (pt) 2003-07-02 2006-09-19 Hoffmann La Roche os compostos de quinazolinona substituìda por arilamina
RU2006102867A (ru) * 2003-07-02 2007-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 5-замещенного хиназолинона
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
US7745451B2 (en) 2005-05-04 2010-06-29 Renovis, Inc. Tetrahydronaphthyridine and tetrahydropyrido[4,3-d]pyrimidine compounds and compositions thereof useful in the treatment of conditions associated with neurological and inflammatory disorders and dysfunctions
JP2009507032A (ja) 2005-09-02 2009-02-19 アボット・ラボラトリーズ 新規なイミダゾ系複素環
CN101336230B (zh) * 2005-11-24 2011-11-23 橘生药品工业株式会社 用于治疗输尿管结石病的药物
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
EP2139334B1 (en) 2007-04-17 2013-07-03 Evotec AG 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
WO2008157751A2 (en) 2007-06-21 2008-12-24 Cara Therapeutics, Inc. Substituted imidazoheterocycles
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
TWI421252B (zh) 2009-07-09 2014-01-01 Irm Llc 用於治療寄生蟲疾病之化合物及組合物
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX2016008062A (es) 2013-12-20 2017-03-09 Esteve Labor Dr Derivados de imidazolilo fusionados, su preparacion y uso como medicamentos.
AU2017266911B2 (en) 2016-05-18 2021-09-02 Array Biopharma, Inc. KRas G12C inhibitors
CN107434786A (zh) * 2016-05-27 2017-12-05 广东东阳光药业有限公司 苯并咪唑化合物及其制备方法
TWI791515B (zh) 2017-04-24 2023-02-11 瑞士商諾華公司 治療療法
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
LT3710439T (lt) 2017-11-15 2023-05-10 Mirati Therapeutics, Inc. Kras g12c inhibitoriai
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
MX2022003537A (es) 2019-09-24 2022-07-11 Mirati Therapeutics Inc Terapias de combinacion.
CN110950886A (zh) * 2019-12-13 2020-04-03 苏州莱克施德药业有限公司 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法
JP2023507571A (ja) 2019-12-20 2023-02-24 ミラティ セラピューティクス， インコーポレイテッド Ｓｏｓ１阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4044136A (en) * 1972-09-09 1977-08-23 Pfizer Inc. Aminoquinazoline therapeutic agents
DE2757925A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
WO2000055143A1 (en) * 1999-03-17 2000-09-21 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators

Also Published As

Publication number Publication date
CA2432578A1 (en) 2002-07-11
DE60110844T2 (de) 2006-01-12
KR20030063490A (ko) 2003-07-28
CN1237060C (zh) 2006-01-18
WO2002053558A1 (en) 2002-07-11
AR035775A1 (es) 2004-07-14
JP4031363B2 (ja) 2008-01-09
ATE295362T1 (de) 2005-05-15
KR100554813B1 (ko) 2006-02-22
ES2241891T3 (es) 2005-11-01
ZA200305038B (en) 2004-09-27
EP1363899B1 (en) 2005-05-11
DE60110844D1 (de) 2005-06-16
CA2432578C (en) 2008-04-01
PE20020735A1 (es) 2002-08-21
CN1484640A (zh) 2004-03-24
EP1363899A1 (en) 2003-11-26
UY27109A1 (es) 2002-07-31
JP2004519454A (ja) 2004-07-02
MXPA03005854A (es) 2003-09-10
PA8536001A1 (es) 2002-08-29

Similar Documents

Publication Publication Date Title
BR0116662A (pt) Derivados de quinazolona como antagonistas receptores alfa 1a/b adrenérgicos
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
UY27336A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
AR033306A1 (es) Compuestos
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
HUP0401333A2 (hu) Spiropirazol vegyületek és ezeket tartalmazó gyógyszerkészítmények
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
UY25804A1 (es) Derivados de 4-aroilpiperidina que son antagonistas de los receptores ccr-3
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
UY27760A1 (es) Nuevos derivados de pirrolidinio.
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
BR0316950A (pt) Derivados de indazol como antagonistas de crf
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
PA8561501A1 (es) Lactamas como antagonistas de taquiquininas
AR045155A1 (es) Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos
BR0214695A (pt) Derivados de pirazol com anel fundido
AR041340A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
BR0214649A (pt) Derivados de aminotetralina como antagonistas do receptor muscarìnico
BR0207795A (pt) Derivados de ácido alcoxicarbonilamino benzóico ou alcoxicarbonilamino tetrazolil fenila como antagonistas de ip
BR0207730A (pt) Derivados de ácido alcoxicarbonila-mino-heteroaril carboxìlico, como antagonistas de ip

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 8A, 9AE 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.